Seglitide

Synonyms: MK-678; L-363586
Seglitide (MK-678) 是一种具有口服活性的选择性 SSTR2 激动剂和 Somatostatin 类似物,同时也表现为竞争性 Somatostatin receptor 拮抗剂,对 SS14、SS25 和 SS28 的 pA2 值分别为 6.50、6.24 和 6.09,对豚鼠离体右心房的心肌收缩力仅产生微弱、短暂的抑制作用,可抑制胰高血糖素分泌并降低循环胰岛素水平,能使 Streptozotocin (MS-Q80520) 诱导的糖尿病大鼠升高的收缩压持续可逆性降低,但对自发性高血压大鼠无作用,还可诱导细胞膜超极化、抑制电兴奋性,并在大鼠离体远端结肠中诱导浓度依赖性收缩及显著脱敏作用,可用于高血压合并胰岛素依赖型糖尿病的相关研究。
产品编号: MS-I18741 纯度: 99.30% CAS No.: 81377-02-8 分子式: C44H56N8O7 分子量: 808.96
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Seglitide (MK-678) 是一种具有口服活性的选择性 SSTR2 激动剂和 Somatostatin 类似物,同时也表现为竞争性 Somatostatin receptor 拮抗剂,对 SS14、SS25 和 SS28 的 pA2 值分别为 6.50、6.24 和 6.09,对豚鼠离体右心房的心肌收缩力仅产生微弱、短暂的抑制作用,可抑制胰高血糖素分泌并降低循环胰岛素水平,能使 Streptozotocin (MS-Q80520) 诱导的糖尿病大鼠升高的收缩压持续可逆性降低,但对自发性高血压大鼠无作用,还可诱导细胞膜超极化、抑制电兴奋性,并在大鼠离体远端结肠中诱导浓度依赖性收缩及显著脱敏作用,可用于高血压合并胰岛素依赖型糖尿病的相关研究。

生物实验数据

生物活性 Seglitide (MK-678) is an orally active, selective SSTR2 agonist and Somatostatin analog that also acts as a competitive Somatostatin receptor antagonist with pA2 values of 6.50, 6.24, and 6.09 for SS14, SS25, and SS28, respectively; it produces only weak and transient inhibition of myocardial contractility in isolated guinea pig right atria, inhibits glucagon secretion and lowers circulating insulin levels, persistently and reversibly reduces elevated systolic blood pressure in Streptozotocin (MS-Q80520)-induced diabetic rats but has no effect in spontaneously hypertensive rats, induces cell membrane hyperpolarization and inhibits electrical excitability, and induces concentration-dependent contraction with marked desensitization in isolated rat distal colon, and can be used for research related to hypertension complicated with insulin-dependent diabetes mellitus.
IC50 & Target

SSTR2

 

体内研究
(In Vivo)

Seglitide (50-1000 µg/rat/day;口服;每日;最长 49 天) 可在 Streptozotocin (MS-Q80520) 诱导的高血压糖尿病雄性 Sprague-Dawley 大鼠中产生可逆且持续的收缩压降低,降幅为 11%-21%,且对相关激素、肾素-血管紧张素系统组分、血糖或生长速率无影响。
Seglitide (50-100 µg/rat/天;口服;每日给予;持续 49 天) 仅能使雄性自发性高血压大鼠的收缩压短暂降低 11%,无持续性降压作用,且对相关激素、肾素-血管紧张素系统组分、血糖或生长速率均无影响。

Animal Model: Sprague-Dawley (male, streptozotocin-induced diabetic hypertension)
Dosage: 50 µg/rat/day (days 1-20); 100 µg/rat/day (days 21-49); 1000 µg/rat/day; 100 µg (acute parenteral)
Administration: p.o. (via drinking water, days 1-20); p.o. (via drinking water, days 21-49); p.o. (unspecified duration); parenteral (single acute dose)
Result: Reduced systolic blood pressure of diabetic rats by 14% after 17 days of 50 µg/rat/day treatment (P=0.05).
Maintained systolic blood pressure significantly reduced by 11-21% relative to untreated diabetic rats over days 24-49 with 100 µg/rat/day dose, matching normotensive control levels (98-118 mmHg; repeated measures ANOVA, P<0.003 vs. untreated diabetic rats, P=0.687 vs. normal rats).
Reversed hypotensive effect 5 days after drug withdrawal, with only a 6% reduction in blood pressure (nsd).
Showed no significant effect on plasma renin activity, angiotensin converting enzyme activity, or aldosterone levels in diabetic rats.
Did not alter circulating insulin or glucagon levels in diabetic rats with 1000 µg/rat/day oral dose, but reduced circulating insulin levels by 44% with acute parenteral 100 µg dose (P<0.05).
Had no significant effect on blood glucose levels or growth rate of diabetic rats over 49 days of treatment.
Animal Model: Spontaneously hypertensive (SH) (male)
Dosage: 50 µg/rat/day (days 1-40); 100 µg/rat/day (days 41-49)
Administration: p.o. (via drinking water, days 1-40); p.o. (via drinking water, days 41-49)
Result: Reduced systolic blood pressure of SH rats by 11% at the 10-day time point (P<0.02), with no significant blood pressure reduction observed in subsequent measurements even after dose escalation to 100 µg/rat/day.
Showed no significant effect on plasma renin activity, angiotensin converting enzyme activity, or aldosterone levels in SH rats.
Did not alter blood glucose levels or growth rate of SH rats over 49 days of treatment.
性状 固体
颜色 White to off-white

化学信息

分子量 808.96
分子式 C44H56N8O7
CAS No. 81377-02-8
别名 MK-678; L-363586

储存&溶解度

溶解度信息
H2O: 1 mg/mL (1.24 mM), Sonication is recommended.
储存方式

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础